Icatibant Product description
is a synthetic peptidomimetic drug consisting of ten amino acids, and acts as an effective and specific antagonist of bradykinin B2 receptors.
It has been approved in the EU for use in hereditary angioedema, and is under investigation for a number of other conditions in which bradykinin is thought to play a significant role.
Icatibant currently has orphan drug status in the United States and FDA approved on August 25, 2011. HAE (hereditary angiodysplasia)
|CAS Registry Number||130308-48-4|
|Categories||BiopharmaceuticalsBiopharmaceuticals (general category); Peptides APIs|
|Sales markets||Western Europe; Eastern Europe; Asia; North America|
Other Polypeptide APIs
|US-DMF LIST–Polypeptide APIs|
|Product Name||US-DMF No.||WC|
|Icatibant Acetate||DMF 28496||YES|
|Octreotide Acetate||DMF 30249||YES|
|Teriparatide Acetate||DMF 32144|
|Ziconotide Acetate||DMF 33139|